

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 64614

Title: Involvement of integrin-activating peptides derived from tenascin-C in colon cancer progression

Reviewer's code: 05230210

Position: Editorial Board

Academic degree: MD

Professional title: Associate Professor

Reviewer's Country/Territory: Egypt

Author's Country/Territory: Japan

Manuscript submission date: 2021-02-21

Reviewer chosen by: Jin-Lei Wang

Reviewer accepted review: 2021-03-26 04:39

Reviewer performed review: 2021-03-30 09:44

Review time: 4 Days and 5 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

I would like to thank the authors for their review on the topic. • The authors presented in this review the studies done on the Tenascin-C and its integrin-related molecular pathways; their relation to colon cancer pathogenesis and potential therapeutic targets. • There was a problem with the word file, all the symbols were not apparent on the word file as (α - β - etc) • Introduction on colon cancer line 304-308 lacks references. Also introduction to the colon cancer needs further detail on the prevalence and current problem of the current therapeutic biological therapy, to be presented in more details. • Please change therapy resistance to>> therapeutic resistance or resistance to therapy in line 179 • Show >>showing in line 135. • The authors should start with colon cancer and then as subcategory CAC. • note: Figure 1 is very similar to your previously published figure , only the spaces were removed(modified from ref 62), also in that previous paper they stated the same theory in details.

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 64614

Title: Involvement of integrin-activating peptides derived from tenascin-C in colon cancer progression

Reviewer's code: 05077871

Position: Peer Reviewer

Academic degree: DSc, MBBS, MRCP

Professional title: Senior Research Fellow, Staff Physician

Reviewer's Country/Territory: United Kingdom

Author's Country/Territory: Japan

Manuscript submission date: 2021-02-21

Reviewer chosen by: Jin-Lei Wang

Reviewer accepted review: 2021-03-27 23:00

Reviewer performed review: 2021-04-06 18:37

Review time: 9 Days and 19 Hours

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Thank your for inviting me to review this article. Thank you to the authors for submitting their perspective on the interesting work on the role of Tenascin-C in colon cancer and colitis associated cancer. In this minireview, the authors have presented the role of TNC, a molecule which has been well described as pro-inflammatory in character and suggested to have an important role in the development of colitis-associated colorectal cancer and malignant progression of colon cancer. The article also mentions the major involvement of its cryptic functional site TNIIIA2 along with new possible prophylactic and therapeutic strategies based on inhibition of the TNIIIA2-induced β 1-integrin activation by peptide FNIII14. Overall, I think the article is very engaging and high quality with appropriate references for each of the points mentioned. Compliments- the article is well structured with a good flow for the reader. The information in the article is written in a manner that will be useful for both for scientists who are not very familiar with the topic and also for experts in the field of CRC. It is both educational and informative. Suggestions to improve manuscript- I have only minor suggestions for the authors to consider- 1. Although this article mainly deals with the role of TNC in malignancy, it has also been shown to be important in both acute and chronic inflammation + fibrogenesis and tissue remodelling. Indeed the authors have touched upon this. However, I suggest adding a small section separately on chronic inflammation before the section that deals with cancer. To accommodate this, the introduction can be shortened if necessary. The chronic inflammation leading to carcinogenesis becomes more evident if this is done. 2. In the CAC section, the authors mention ATN-161, a peptidic antagonist of integrin α 5 β 1 and α v β 3. In this experimental model, was it known through which sub-unit the anti-cancer properties were exerted? If known please mention including if there are any pre-clinical models in progress. 3.



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

Indeed the authors end with a note mentioning the potential for therapeutic targeting, which is encouraging. If any models are known that are in progress which take us closer to translation of these targets, it would be useful to mention here. 4. The figures add to the flow of the article and are clearly illustrated. Thank you for the very interesting work.